Intercept Pharmaceuticals (NASDAQ:ICPT) has gone on an unprecedented run. It nearly quadrupled on Thursday before adding another 60% on Friday, to become a two-day six-bagger. This all happened after lead drug candidate OCA had a trial halted because the drug was working so well in patients with NASH, a disease with no approved treatments and a leading cause of liver failure.

However, what goes up must come down -- at least a little.

Shares of Intercept fell about 20% today. This isn't just a story of investors who are taking a cold shower over the weekend and taking profits Monday. Potentially concerning data came out from the company's groundbreaking phase 2 trial, and Intercept's CEO threw a wet blanket on bullish investors by suggesting a partnership.

Watch as Motley Fool health-care analyst David Williamson discusses why the new data raised red flags for investors, why the CEO's comments were poorly received, and why Intercept is such a risky, but potentially incredibly rewarding, stock.